The Clinical Result of Somatuline(R) Therapy in Thyroid Ophthalmopathy.
- Author:
Helen LEW
1
;
Su Yeon NAM
;
Sang Yeul LEE
;
Sung Joo KIM
Author Information
1. Department of Ophthalmology, Pundang CHA Hospital, Medical College, Pocheon CHA University.
- Publication Type:Original Article
- Keywords:
Lanreotide;
Somatostatin;
Thyroid eye disease
- MeSH:
Exophthalmos;
Eye Diseases;
Humans;
Octreotide;
Self-Assessment;
Somatostatin;
Thyroid Gland*
- From:Journal of the Korean Ophthalmological Society
2001;42(10):1377-1382
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Octreotide, a potent synthetic somatostatin (SM) analogue, was recently evaluated and found to have a beneficial effect in thyroid eye disease (TED). Lanreotide (LRT: Somatuline(R)), a new SM analogue, is more active and has a much longer duration of action. The aim of this study was to report the therapeutic effect of LRT on the treatment of TED. METHODS: Four patients of mean age 42.5 years had severe acute thyroid-related ophthalmopathy symptoms. The NOSPECS system was applied in this study to evaluate the response to treatment. They received 40 mg LRT i.m. every 2 weeks over a period of 3 months. RESULTS: All of them showed a significant improvement of acute inflammatory symptoms in both eyes. The average of TED score was 3.6, while it was 6.3 before the injection. Average clinical activity score of pre-injection was 4.1 and it markedly decreased to 1.3, and the self assessment score was 1.4, which means a moderate satisfaction. The amount of proptosis was found to decrease about 3.0 mm. CONCLUSIONS: We report our clinical experience that LRT has a beneficial effect on active TED and it is a good therapeutic modality for medical treatment.
